Suppr超能文献

放射性示踪剂剂量减少三分之一:儿科 [F]氟代脱氧葡萄糖 PET/CT 和 PET/MR 成像二十年的进展。

A third of the radiotracer dose: two decades of progress in pediatric [F]fluorodeoxyglucose PET/CT and PET/MR imaging.

机构信息

Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.

University of Zurich, Zurich, Switzerland.

出版信息

Eur Radiol. 2024 May;34(5):3252-3259. doi: 10.1007/s00330-023-10319-6. Epub 2023 Oct 19.

Abstract

OBJECTIVES

To assess the evolution of administered radiotracer activity for F-18-fluorodeoxyglucose (18F-FDG) PET/CT or PET/MR in pediatric patients (0-16 years) between years 2000 and 2021.

METHODS

Pediatric patients (≤ 16 years) referred for 18F-FDG PET/CT or PET/MR imaging of the body during 2000 and 2021 were retrospectively included. The amount of administered radiotracer activity in megabecquerel (MBq) was recorded, and signal-to-noise ratio (SNR) was measured in the right liver lobe with a 4 cm volume of interest as an indicator for objective image quality. Descriptive statistics were computed.

RESULTS

Two hundred forty-three children and adolescents underwent a total of 466 examinations. The median injected 18F-FDG activity in MBq decreased significantly from 296 MBq in 2000-2005 to 100 MBq in 2016-2021 (p < 0.001), equaling approximately one-third of the initial amount. The median SNR ratio was stable during all years with 11.7 (interquartile range [IQR] 10.7-12.9, p = 0.133).

CONCLUSIONS

Children have benefited from a massive reduction in the administered 18F-FDG dose over the past 20 years without compromising objective image quality.

CLINICAL RELEVANCE STATEMENT

Radiotracer dose was reduced considerably over the past two decades of pediatric F-18-fluorodeoxyglucose PET/CT and PET/MR imaging highlighting the success of technical innovations in pediatric PET imaging.

KEY POINTS

• The evolution of administered radiotracer activity for F-18-fluorodeoxyglucose (18F-FDG) PET/CT or PET/MR in pediatric patients (0-16 years) between 2000 and 2021 was assessed. • The injected tracer activity decreased by 66% during the study period from 296 megabecquerel (MBq) to 100 MBq (p < 0.001). • The continuous implementation of technical innovations in pediatric hybrid 18F-FDG PET has led to a steady decrease in the amount of applied radiotracer, which is particularly beneficial for children who are more sensitive to radiation.

摘要

目的

评估 2000 年至 2021 年间,0-16 岁儿科患者接受 F-18-氟脱氧葡萄糖(18F-FDG)PET/CT 或 PET/MR 检查时,放射性示踪剂(氟代脱氧葡萄糖)的给药活度的演变。

方法

回顾性纳入 2000 年至 2021 年间行 18F-FDG PET/CT 或 PET/MR 全身成像的≤16 岁儿科患者。记录给药放射性示踪剂活度(以兆贝克勒尔(MBq)为单位),并以右肝 4cm 体积的兴趣区作为客观图像质量的指标,测量信噪比(SNR)。计算描述性统计数据。

结果

共有 243 名儿童和青少年进行了 466 次检查。2000-2005 年,每公斤体重注射的 18F-FDG 活性中位数为 296MBq,2016-2021 年降至 100MBq(p<0.001),相当于初始剂量的三分之一。所有年份的中位数 SNR 比值均稳定在 11.7(四分位距 [IQR] 10.7-12.9,p=0.133)。

结论

过去 20 年来,儿童接受的 18F-FDG 剂量大幅减少,而客观图像质量不受影响。

临床相关性声明

过去二十年,儿科 F-18-氟脱氧葡萄糖 PET/CT 和 PET/MR 成像中放射性示踪剂剂量大幅减少,这突显了儿科 PET 成像中技术创新的成功。

要点

  1. 评估了 2000 年至 2021 年间,0-16 岁儿科患者 F-18-氟脱氧葡萄糖(18F-FDG)PET/CT 或 PET/MR 检查时,放射性示踪剂(氟代脱氧葡萄糖)的给药活度的演变。

  2. 研究期间,注射示踪剂的活性从 296MBq 下降 66%至 100MBq(p<0.001)。

  3. 连续实施儿科混合 18F-FDG PET 技术创新,导致应用放射性示踪剂的数量稳步下降,这对儿童尤其有益,因为儿童对辐射更敏感。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d53/11126459/1355b0cfadd6/330_2023_10319_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验